CAS 236395-14-5|Eslicarbazepine acetate
| Common Name | Eslicarbazepine acetate | ||
|---|---|---|---|
| CAS Number | 236395-14-5 | Molecular Weight | 296.320 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 427.4±55.0 °C at 760 mmHg |
| Molecular Formula | C17H16N2O3 | Melting Point | 183-185ºC |
| MSDS | ChineseUSA | Flash Point | 212.3±31.5 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | eslicarbazepine acetate |
|---|---|
| Synonym | More Synonyms |
Eslicarbazepine acetate BiologicalActivity
| Description | Eslicarbazepine acetate, an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. |
|---|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>Beta-secretaseSignaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Neurological Disease |
| In Vivo | Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability[1]. |
| References | [1]. Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 427.4±55.0 °C at 760 mmHg |
| Melting Point | 183-185ºC |
| Molecular Formula | C17H16N2O3 |
| Molecular Weight | 296.320 |
| Flash Point | 212.3±31.5 °C |
| Exact Mass | 296.116089 |
| PSA | 72.63000 |
| LogP | 1.70 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.655 |
| InChIKey | QIALRBLEEWJACW-INIZCTEOSA-N |
| SMILES | CC(=O)OC1Cc2ccccc2N(C(N)=O)c2ccccc21 |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
Articles2
More Articles| Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42 , 600-608, (2001) BIA 2-093 [(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide] is endowed with an anticonvulsant potency similar to that of carbamazepine (CBZ), but produces less cognitive and motor... | |
| The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem. Int. 40 , 435-440, (2002) (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (BIA 2-093) is endowed with high anticonvulsant activity and shares with carbamazepine (CBZ) and oxcarbazepine (OXC) the capability... |
Synonyms
| (10S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate |
| 5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)- |
| Exalief |
| EslicarbazepineAcetate |
| S-(−)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide |
| [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate |
| (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide |
| Eslicarbazepine acetate |
| Aptiom |
| BIA 2-093 |
| Zebinix |
| UNII-BEA68ZVB2K |
| Eslicarbazepine (acetate) |
